Phosphatase Regulation of CFTR

John W. Hanrahan

Tang Zhu

L. Daniel Howell
Liberty University, dhowell@liberty.edu

Follow this and additional works at: http://digitalcommons.liberty.edu/bio_chem_fac_pubs

Recommended Citation
http://digitalcommons.liberty.edu/bio_chem_fac_pubs/54

This Article is brought to you for free and open access by the Department of Biology and Chemistry at DigitalCommons@Liberty University. It has been accepted for inclusion in Faculty Publications and Presentations by an authorized administrator of DigitalCommons@Liberty University. For more information, please contact scholarlycommunication@liberty.edu.
Chapter 2

Phosphatase Regulation of CFTR

John W. Hanrahan, Tang Zhu and L. Daniel Howell

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is tightly regulated by the opposing actions of protein kinases and phosphatases. Its phosphorylation and activation by protein kinases A (PKA) and C (PKC) have been studied in some detail but phosphatase regulation of the channel has received less attention. Several phosphatases may control CFTR in various cell types, however in epithelia most deactivation is mediated by a membrane-bound phosphatase with functional properties resembling those of PP2C, the prototypic member of the PPM gene family of serine/threonine phosphatases. The PP2C-like phosphatase requires Mg2+, is insensitive to the inhibitors okadaic acid and calyculin A, does not require Ca2+ or calmodulin, and is inhibited non-specifically by phenylimidazothiazoles. It is closely associated with CFTR and can be co-immunoprecipitated or co-purified from cell lysates by affinity chromatography with, or without, pretreatment with chemical crosslinking reagents. Current efforts are directed towards identifying the phosphatase at the molecular level; i.e., determining if it is a novel isoform or alternatively spliced variant of a known PP2C isoform, or a new membrane-targeted phosphatase in the PPM family. Identifying and characterizing the phosphatase will open many new avenues of investigation into basic aspects of CFTR regulation, and may have clinical significance since the phosphatase is a potential target for pharmacotherapies to treat cystic fibrosis and secretory diarrhea.

Introduction

CFTR is a non-rectifying, low-conductance chloride channel in epithelia and other cells which is activated in different preparations by cAMP-mobilizing agonists such as prostaglandin E2, epinephrine, vasoactive intestinal peptide, adenosine and secretin (see ref. 1). Gating of the CFTR pore is nucleotide dependent and tightly regulated by phosphorylation. In addition to its role in mediating plasma membrane chloride conductance, CFTR also influences the activity of other channels and transporters through mechanisms that are poorly understood and, in view of the large number and diversity of proteins affected, probably indirect. Some of these regulatory effects (e.g., down-regulation of epithelial sodium channels) require phosphorylation of CFTR whereas others (e.g., up-regulation of glutathione release) apparently do not. Although phosphatases may control both chloride conductance and the regulatory effects of CFTR, this chapter focuses exclusively on their role in regulating CFTR channel activity.

CFTR Phosphorylation

Activation of apical membrane chloride conductance by cAMP, the rate-limiting step for transepithelial chloride secretion, was established by the early work of M. Field, R. Frizzell, S.
Phosphatase Regulation of CFTR

The Cystic Fibrosis Transmembrane Conductance Regulator

Klyce and others (see ref. 4). It is now generally accepted that the channel mediating this conductance is CFTR, which is phosphorylated and strongly activated by protein kinase A (PKA). Hypersstimulating PKA with forskolin leads to the addition of about 5 moles of PO₄ per mole of CFTR in vivo, although this is a lower limit since it is likely that some ATP fails to acquire [³²P]PO₄ at the γ position when cells are metabolically labeled. Higher stoichiometries are achieved in vitro through phosphorylation of additional low-affinity sites. This could be viewed as an artifact of the high kinase and low phosphatase activities present in vitro, but it could also be argued that phosphorylation of the low-affinity sites occurs in vivo but is not detected due to the technical limitations of in vivo experiments; i.e., the lower specific activity of [³²P]ATP in cells and the labile nature of the phosphoryl groups at “weak” sites. Removing the nine strong dibasic consensus sequences on the R domain and one additional dibasic site proximal to the first nucleotide binding domain (NBD1) reduces in vitro phosphorylation by more than 90% and channel open probability by about half in excised membrane patches that are exposed to high PKA activity. While the precise number and identity of the consensus sequences that are phosphorylated under physiological conditions remains uncertain, it is clear that PKA acts at multiple sites and that even the “weak” PKA sites are likely to have functional significance since they are almost perfectly conserved from cartilaginous fishes to humans.

The mechanisms by which phosphorylation and dephosphorylation of the R domain regulate channel activity appear complex. Phosphorylation induces small changes in the secondary structure of a polypeptide comprising the R domain and distal region of NBD1, and these are not observed when the distal part of NBD1 is not included in the construct. Rather than regulating NBD function, phosphorylation may allow the efficient transduction of conformational changes induced by nucleotide interactions at the NBDs to the membrane domains (see ref. 1 for review). Adding dephosphorylated R domain inhibits wild-type CFTR channels incorporated into planar bilayers, and pre-phosphorylating the exogenous domain with PKA prevents inhibition. Adding dephosphorylated R domain does not inhibit a mutant lacking the distal two thirds of the R domain when studied by patch clamping excised patches, however when pre-phosphorylated and added to excised patches, it does increase the spontaneous activity of this mutant. While the latter implies a positive role of phosphorylated R domain in sustaining channel activity, it is surprising to “split” channels lacking the entire R domain when expressed in Xenopus oocytes argues strongly that the primary role of the R domain is as a negative regulator (when unphosphorylated) and that phosphorylated R domain is not essential for channel gating.

Mutating two potential PKA sites on the R domain (S757 and S768) enhances activation in oocytes, suggesting they may act like channel “brakes”. If so, this has interesting implications for phosphatases, which have a similar physiological role, since to remain phosphorylated (and inhibitory) in a particular cell type, those inhibitory sites would need to be either more resistant to the phosphatases in that cell, or more susceptible to basal PKA activity. Recent studies suggest a negatively charged, predicted helical region distal to the phosphorylation sites on the R domain (S757-S768) also plays a role in regulation by phosphorylation since deleting this region causes the channel to become unresponsive to PKA. Removing negative charges in this region or disrupting its helical structure by mutagenesis abolishes inhibition by dephospho-R domain and stimulation by PKA, respectively.

Charge in the R domain has been considered a determinant of activation because a spontaneously active mutant when patches are isolated from Chinese hamster ovary cells (Fig. 1), or in 1-2 minutes when excised at room temperature. Deactivation in about 10 seconds at 37°C when patches are isolated from Chinese hamster ovary cells (Fig. 1), or in 1-2 minutes when excised at room temperature. The rundown is fully reversed by adding PKA catalytic subunit to the bath within the first few minutes after excision, and is more rapid than the reaction induced by exposure to high PKA activity. Similar rundown is observed when patches are excised from an airway epithelial tumor cell line expressing endogenous CFTR or an immortalized airway epithelial cell line transfected with CFTR cDNA, therefore membrane-bound phosphatases probably regulate CFTR channels in cells that normally express them, not only heterologous expression systems. The extent of rundown and the relative importance of particular phosphatases may vary with cell type since it seems to be less dramatic than the rundown observed in Xenopus oocytes. A large component of the rundown is due to the membrane-impermeant PP2A inhibitor microcin in guinea pig myocytes.

That said, if that CFTR-mediated currents in epithelial cells do have the same pharmacological properties as those described in patches excised from CHO and most other mammals.

Phosphatase Regulation of CFTR

stimulate channel activity through several mechanisms; e.g., enhanced nucleotide binding, a more stable ATP-bound transition state at NBD1 or accelerated hydrolysis at NBD2, or improved coupling of conformational changes to the channel gate. Consistent with the binding hypothesis, PKA phosphorylation causes a modest increase in the rate of hydrolysis and shifts its dependence to lower ATP concentrations. The significance of such alterations in the apparent Km for hydrolysis need to be established, particularly when much of the gating does not depend on hydrolysis. A shift in the ATP dependence of open probability is seen during patch clamp experiments when wild-type channels are phosphorylated by PKA, or when low-phosphorylation mutants (e.g., 4SA, 10SA) are compared in excised patches with strongly phosphorylated wild-type channels. However these functional effects would also be explained by a downstream mechanism in which dephosphorylation of the R domain hinderers transduction of conformational changes from the NBDs to the membrane domains. Exposure to PKC (without PKA) causes a small increase in open probability that is not abolished by pre-treating excised patches with protein phosphatase, however a more striking effect of PKC is to enhance the subsequent responsiveness of CFTR to PKA stimulation. PKC increases the rate and magnitude of activation, and this is mediated by direct PKC phosphorylation of CFTR since it is abolished by mutating serines or threonines at all nine PKC consensus sequences between the Walker B consensus in NBD1 and TM7 of the second transmembrane domain to alamines. These potential PKC sites, which are defined by the consensus R/K₃₁₋₁₅, X₂₋₄, S/T, X₂₋₄, R/K₃₁₋₁₅ include T582, T604, S641, T682, S686, S707, S790, T791, S809. Multiple PKC sites may be involved in modulating regulatory activation by PKA, since PKC decreases not only inhibited but not abolished by removing the two (S686, S790) where phosphorylation has been directly demonstrated. It seems unlikely that the mechanism by which PKC enhances PKA responses will be understood until the nature of PKA regulation is established.

Deactivation of CFTR Channels by a Membrane-Bound Phosphatase

cAMP is a diffusible second messenger that regulates growth, metabolism and many other cellular functions not obviously related to transepithelial chloride secretion. CFTR must be efficiently dephosphorylated in vivo to maintain low resting chloride conductance and ensure that CI secretion is only increased by appropriate stimuli and is readily reversible. Tonic suppression of CFTR by a phosphatase would effectively raise its threshold for activation and minimize responses to irrelevant signals.

Evidence that CFTR is indeed regulated by a membrane-localized phosphatase came from the spontaneous “rundown” of channel activity that occurs after patches are excised from cAMP stimulated cells in bath solution lacking PKA. Channels deactivate in about 10 seconds at 37°C when patches are isolated from Chinese hamster ovary cells (Fig. 1), or in 1-2 minutes when excised at room temperature. The rundown is fully reversed by adding PKA catalytic subunit to the bath within the first few minutes after excision, and is more rapid than the reaction induced by exposure to high PKA activity. Similar rundown is observed when patches are excised from an airway epithelial tumor cell line expressing endogenous CFTR or an immortalized airway epithelial cell line transfected with CFTR cDNA, therefore membrane-bound phosphatases probably regulate CFTR channels in cells that normally express them, not only heterologous expression systems. The extent of rundown and the relative importance of particular phosphatases may vary with cell type since it seems to be less dramatic than the rundown observed in Xenopus oocytes. A large component of the rundown is due to the membrane-impermeant PP2A inhibitor microcin in guinea pig myocytes. That said, if that CFTR-mediated currents in epithelial cells do have the same pharmacological properties as those described in patches excised from CHO and most other mammals.
subunit binds to a highly conserved sequence (RVxF) on an accessory subunit, which targets familiar and reflects the fact that the phosphatase regulating CFTR is still known by its functional subunit also has multiple splice variants. In most instances, a cleft in the holoenzyme to various cellular locations (see ref. 41). 

PPC2 in the bath. B, Number of patches with active channels as a function of time after excision (i.e., 6s). 31, 35, 37 (see above). This implies that the predominant CFTR phosphatase in epithelia is the same membrane-bound enzyme that deactivates CFTR in excised patches from cells. 

Characteristics of Protein Phosphatases

Mammalian Ser/Thr phosphatases were classified as type 1 (PP1) or type 2 (PP2A, PP2B, PP2C) based on their functional properties. 38 A more recent system based on gene relatedness places PP1, PP2A and PP2B in the "PPP family" along with several newly-cloned phosphatases (i.e., PP4, PP5, PP6, PP7; see below). PP2C and its orthologs such as ABI1 in Arabidopsis and PTCl in S. cerevisiae are distinct and have been placed in the "PPM family" (for evolutionary analyses see. 39, 40). The functional scheme (PP1, PP2A, etc.) is used in this review because it is familiar and reflects the fact that the phosphatase regulating CFTR is still known by its functional properties rather than by its sequence. 

The PP1 family of protein phosphatases dephosphorylates the β-subunit of phosphorylase kinase and is sensitive to the thermostable proteins Inhibitor 1 and Inhibitor 2 (see Table 1). PP1 holoenzymes are heterodimers of catalytic and accessory subunits. There are at least three catalytic subunit isoforms and about 50 known or putative accessory subunits. The PP1β catalytic subunit also has multiple splice variants. In most instances, a cleft in the PP1 catalytic subunit binds to a highly conserved sequence (RVxF) on an accessory subunit, which targets the holoenzyme to various cellular locations (see ref. 41). PP1 has diverse functions that include smooth muscle relaxation, pre-mRNA splicing, synaptic transmission, and the regulation of epithelial transport. 

The PP2 family dephosphorylates the α-subunit of phosphorylase kinase and is insensitive to the thermostable proteins Inhibitor 1 and Inhibitor 2. PP2 phosphatases have been further sub-divided into types 2A (PP2A), 2B (PP2B) and 2C (PP2C) according to their metal ion requirements and inhibitor sensitivities. Active PP2A does not require divalent cations or other cofactors for enzymatic activity and is a heterotrimer of "A" (catalytic), "B" (regulatory), and "C" (catalytic) subunits, all of which have multiple isoforms and splice variants. It is implicated in regulating metabolism, DNA replication, transcription, RNA splicing, translation, cell cycle progression and many other cellular functions. Of particular interest for CFTR research is its role in controlling signaling pathways, since it has been reported to upregulate four protein kinases and downregulate 29 others, including PKA and PKC. 42 This complicates the interpretation of any in vivo phosphorylation that might be induced by inhibitors such as calyculin A, even though they are relatively specific for PP2A when assayed in vitro. Phosphatases in the PP2B (calcineurin) sub-family have "A" (catalytic) and "B" (regulatory) subunits and require the binding of Ca^2+ and calmodulin for enzymatic activity. PP2B regulates events at neuronal postsynaptic densities, microtubules of the cytoskeleton, and signal transduction in T cells, where it is a target for the immunosuppressive drugs cyclosporin and FK506. Several other protein phosphatases (PP3 – PP7) have been reported in mammalian cells, although the existence of PP3 has been questioned. 43 PP4-PP7 all belong to the PPP gene family.
and have sequences resembling PP2A. PP7 is Mg\(^{2+}\) dependent and insensitive to okadaic acid, however its mass (75 kD) and restricted tissue distribution (retina) argue against a role in regulating CFTR (see below). For comprehensive accounts of serine/threonine phosphatases, the reader is directed to the many excellent general reviews of the early\(^ {44-47}\) and more recent literature.\(^ {41,45,46,52}\)

PP2C is the prototypic member of the PPM gene family and has no significant sequence homology with PP1, PP2A or PP2B\(^ {53}\) although its architecture and proposed catalytic mechanism are similar (see refs. 50, 54). First identified chromatographically as a glycosynthetic phosphatase,\(^ {55}\) it was later characterized as a divalent cation-dependent (Mg\(^{2+}\)-Mn\(^{2+}\)-Co\(^{2+}\)) protein phosphatase of about 49 kDa.\(^ {56}\) An enzyme with properties resembling glycosynthetic phosphatase but which dephosphorylates phosphocasein\(^ {57}\) and myosin light chains\(^ {58}\) is characterized in cardiac and smooth muscle, respectively. cDNA cloning has identified several PPMs in mammals (Fig. 2): \(\alpha-1,\alpha-2,\alpha-3\) forms (A. Cherniack, S. Nicoloro, J. Buxton, A. Bose, M. Emoto, S. Waters, and M. Czech; NCBI accession # AF259672.I, Finn13/PP2Cy, PDP·1) which were cloned from different species. PP2C\(\beta\) has at least six variants differing at their C termini, probably through alternative splicing: \(\alpha-1,\beta-2,\beta-3,\beta-4,\beta-5,\beta-6\).\(^ {59}\) Fig. 3 shows an alignment of the C terminal amino acids of the \(\alpha\) and \(\beta\) variants.

PP2C\(\alpha\) was purified to homogeneity from rat liver and turkey gizzard but is expressed in many other tissues including skeletal muscle, kidney, and cerebellum. There are several variants including the original \(\alpha-1,\beta-2\) and the much shorter \(\alpha-2\) and \(\alpha-3\) forms (A. Cherniack, S. Nicoloro, J. Buxton, A. Bose, M. Emoto, S. Waters, and M. Czech; NCBI accession # AF259672.1, 2000), which were cloned from different species. PP2C\(\beta\) has at least six variants differing at their C termini, probably through alternative splicing: \(\alpha-1,\beta-2,\beta-3,\beta-4,\beta-5,\beta-6\).\(^ {59}\) Fig. 3 shows an alignment of the C terminal amino acids of the \(\alpha\) and \(\beta\) variants.

PP2C\(\alpha\) was purified to homogeneity from rat liver and turkey gizzard but is expressed in many other tissues including skeletal muscle, kidney, and cerebellum. There are several variants including the original \(\alpha-1,\beta-2\) and the much shorter \(\alpha-2\) and \(\alpha-3\) forms (A. Cherniack, S. Nicoloro, J. Buxton, A. Bose, M. Emoto, S. Waters, and M. Czech; NCBI accession # AF259672.1, 2000), which were cloned from different species. PP2C\(\beta\) has at least six variants differing at their C termini, probably through alternative splicing: \(\alpha-1,\beta-2,\beta-3,\beta-4,\beta-5,\beta-6\).\(^ {59}\) Fig. 3 shows an alignment of the C terminal amino acids of the \(\alpha\) and \(\beta\) variants.

One homologue was identified in rat liver but it is ubiquitously expressed. PP2C\(\beta\) is more abundant in mouse heart and brain whereas the PP2C\(\beta\)3 and PP2C\(\beta\)4 forms have been reported only in testes.\(^ {60}\) PP2C\(\beta\)5 is a "predicted" variant since it was originally identified by RT-PCR using an upstream primer that anneals about half way through the coding region, although Northern blots analyzed with a C-terminal cDNA probe suggest a full-length message is expressed in mouse testes and intestine.\(^ {60}\) Finally, PP2C\(\beta\)6 is the most divergent variant of the beta isoform, being only 749 in this to the others even without its long C-terminal tail. It is abundant in human skeletal muscle, heart and liver, but also detected in brain, placenta, kidney and pancreas.\(^ {70}\) Other members of the PPM family are not discussed in detail because they lack the epitope recognized by our antibody against the CFTR-associated phosphatase (see below) and because their cellular locations may be unlikely to regulate CFTR (e.g. PDP is mitochondrial; FIN13/PP2C\(\beta\) and Wip1 are nuclear).

The catalytic domain of PP2Cs consists of the N-terminal ~290 amino acids, which are well conserved among isoforms. When the structure of PP2C\(\alpha\) was solved by X-ray crystallography it was found to have a novel fold consisting of a central beta-sandwich and two manganese ions surrounded by alpha-helices.\(^ {34}\) Mn\(^{2+}\)-bound water was postulated to act as a nucleophile during catalysis,\(^ {30,34,41,42}\) which would account for the strict dependence of enzymatic activity on Mg\(^{2+}\), Mn\(^{2+}\), or Fe\(^{2+}\).\(^ {72,73}\) Functional studies of mouse PP2C\(\beta\)-1 mutants confirmed that metal ions bind at acidic amino acids in the fold (i.e., Glu37, Asp38, Asp60 and Asp239).\(^ {74}\) Other substrates of mammalian PP2Cs include AMP kinase,\(^ {75}\) moesin,\(^ {76}\) and kinases in stress-activated signaling pathways. For example the MAP kinase kinase kinase (MAPKKK) TAK1, which is activated by environmental stress and inflammatory cytokines, is down-regulated by PP2C\(\beta\)-2\(^ {32,74}\) whereas the downstream kinases MKK and p38 MAPK are down-regulated by PP2C\(\beta\)-1.\(^ {66}\) There may be many isoforms and splice variants of PP2C, each having a different set of phosphoprotein substrates.

Like Real Estate, What Counts Is Location, Location and Location

Serine/threonine phosphatases have broad and overlapping specificities when assayed in vitro (see ref. 44). Their specificity in vivo is often due to targeting to particular substrates by specific regulatory subunits or accessory proteins. For example in neurons, PP1 is targeted to AMPA-type glutamate receptors by a protein called spinophilin.\(^ {78}\) PP1 constitutively down-regulates AMPA currents and this is dependent on targeting. Introducing a phospho-peptide that disrupts the binding of PP1 also abolishes its ability to deactivate the AMPA current. Similar targeting of PP1 to glycogen particles is mediated by the accessory subunit GL, which has the consensus motif RXXE. This sequence is found on other PP1 targeting subunits and has recently been demonstrated near the amino terminus of NKC11, the sodium-potassium-chloride co-transporter.\(^ {79}\) Altering the consensus abolishes PP1 co-immunoprecipitation with the co-transporter, slows dephosphorylation, and increases NKC11-mediated ion transport. Like PP1, PP2A and PP2B are targeted by specific regulatory (i.e., B) subunits that influence its enzymatic activity in vivo.\(^ {80}\) Different isoforms of the regulatory subunit may have specific address; for example, PP2A is targeted to the microtubule associated protein Tau by B\(_{\alpha}\) and B\(_{\beta}\), but not by the B\(_{\gamma}\) regulatory subunit.\(^ {81}\) Other substrates of PP2A include voltage-gated sodium channels, soluble CaMKII, and neurofilaments. Only a few PP2B targeting subunits have been identified to date. One is AKAP7 (A-kinase Anchor- ing Protein (A-KAP)), which targets PP2B to postsynaptic density and provides a scaffold for the binding of PKA and PKC.\(^ {82}\) Dynamin, plasma membrane Ca channels and IP3 receptors are also known substrates for PP2B.
Figure 3. Alignment of the carboxyl-terminal regions of PP2Cα and β isofoms, starting at amino acid position 276–281. Note the strong conservation of N-terminal amino acids <290, which are in the catalytic domain. The coils above the alignments indicate regions that are predicted to be α-helical. PP2Cα-2 and α-3 are truncated and have distinct C-termini. PP2Cβ also differ in this region, however note that β-5 is a chimer of β-1 (AGDLEDILVAL) and β-3 (FYQPSLAYSNDVFLL).
Comparing the Deactivation of CFTR by Endogenous and Exogenous Protein Phosphatases

To help identify endogenous phosphatases that regulate CFTR, spontaneous deactivation of CFTR channels in excised patches has been compared with that induced by adding exogenous phosphatases. Fortunately channels in patches from baby hamster kidney (BHK) cells often do not exhibit rundown, making it possible to assay the effects of exogenous phosphatases. Adding PP2A catalytic subunit from smooth muscle, PP2Cα from turkey gizzard, or bovineintestinal alkaline phosphatase reduces channel activity by more than 90%, but at different rates depending on the phosphatase used. PP2C is most efficient, causing deactivation comparable to the rundown that is mediated by endogenous phosphatase in CHO and other cells. Deactivation by PP2A is somewhat slower, and that by alkaline phosphatase occurs after a delay of several minutes. By contrast, PP2B from bovine brain is much less effective in deactivating CFTR channels, and recombinant human PP1 has little effect, yielding the sequence PP2C > PP2A > PP2B >> PP1 for deactivation of channels by addition of exogenous phosphatases to excised patches. Exposure to PP2A or PP2C causes deactivation of macromolecular CFTR currents and dephosphorylates CFTR protein. In addition to their similar time courses, spontaneous rundown and deactivation by exogenous PP2C are both magnesium dependent, and have similar effects on single channel kinetics. Thus, as Po declines during spontaneous rundown or exposure to exogenous PP2C, there is no obvious reduction in the mean duration of bursts of channel openings, and the fall in Po is due to lengthening of the intervals between open bursts. By contrast, addition of exogenous PP2A causes slower deactivation, and this decline in Po is accompanied by a decrease in burst duration. Interestingly, residual channel activity is observed even after prolonged exposure to purified PP2C or PP2A whereas spontaneous rundown is usually complete. This might reflect the involvement of multiple endogenous phosphatases during rundown that cannot be mimicked by individual enzymes. Alternatively, dephosphorylation by exogenous, soluble PP2Cα may be inherently less effective than the membrane-bound form that is associated with CFTR. The properties of the membrane-bound phosphatase in excised patches, which are based mainly on single channel results obtained using patches from CHO from BHK cells, are entirely consistent with those of CFTR-mediated current across T84 epithelial cell monolayers, which is insensitive to high concentrations of the PP2A/PP1 inhibitor calyculin A (see below).

Pharmacology Suggests the Membrane-Associated CFTR Phosphatase Is Related to PP2C

PP1 and PP2A are both sensitive to calyculin A at nanomolar concentrations. All the PP's except PP2C and PP7 are inhibited by okadaic acid, albeit at widely varying concentrations. PP4 and PP6 resemble PP2A and are sensitive to the same inhibitors (reviewed by ref. 43). PP2B is distinguished by its sensitivity to deltamethrin, cyclosporin, and FK506. Specific inhibitors of PP2C are not presently available.

Channel rundown is inhibited slightly or not at all by okadaic acid, but is slowed four-fold by the phenylmethylsulphonyl fluoride (PMSF) inhibitor levanilamide. Well known inhibitors of alkaline phosphatase isozymes from liver, bone, and kidney (but not from intestine) are less active. Phosphatase inhibition results obtained using patches from Chinese hamster ovary or human airway cells are used. These drugs stimulate mutant G551D channels that are processed and trafficked to the plasma membrane, although they do not respond to forskolin stimulation (Fig. 4). However, higher phenylmethylsulphonyl fluoride concentrations are needed to inhibit rundown or stimulate channel activity on intact cells (≥ 100 μM) than to inhibit of alkaline phosphatases (≥ 11 μM; ref. 93, and PP1, PP2A, PP2B and PP2C are all sensitive to bромотерамозин at concentrations that stimulate CFTR. These results establish that, at least in principle, phosphatase inhibitors may benefit CF patients who have mutations that allow normal processing of CFTR, although more potent and selective inhibitors are clearly needed.

Studying excised patches could give a false impression regarding the relative importance of different phosphatases, since any soluble enzymes would be lost when deactivation is studied under these conditions. The most compelling evidence that CFTR is down-regulated predominantly by the PP2C-like phosphatase in intact cells rather than by PP2A or other cytosolic phosphatases comes from the rapid decline in chloride current across T84 monolayers that occurs following washout of cAMP or forskolin. Deactivation of transepithelial current is unaffected by okadaic acid or calyculin A, even at toxic concentrations that would inhibit any contributions by PP1 or PP2A (Fig. 5).

Okadaic acid (10−8 M) does slow the deactivation of CFTR currents in permeabilized sweat ducts (when studied under low-Mg2+ conditions that would inhibit any contribution by PP2C). Partial inhibition of whole cell CFTR current deactivation in cardiac cells by microcystin or okadaic acid suggest PP2A can play a significant role in those cells. However, some results with transfected cells are difficult to reconcile. For example, exogenous PP1 and PP2B have little effect on macroscopic CFTR current when added to patches excised from fibroblasts, yet PP2B has been proposed as the endogenous phosphatase regulating heterologous CFTR channels in those cells based on their stimulation by cyclosporin A and deltamethrin.

Dephosphorylation of individual sites has not yet been studied experimentally by phosphopeptide mapping or mass spectrometry, although this will be essential to fully understand deactivation of CFTR, particularly when stimulatory and inhibitory sites weaken the correlation between total phosphorylation and channel activity. However, such studies would be most informative if carried out with the membrane-bound phosphatase. Moreover, if the phosphatase operates within a regulatory complex, dephosphorylation of critical sites on CFTR may depend not only on having the right phosphatase but also its orientation relative to that of the R domain. If dephosphorylation is not recapitulated in vitro using soluble enzymes, it may be necessary to study intact complexes.

Evidence That CFTR and Its Phosphatase Are Part of a Regulatory Complex

Comparing deactivation by the endogenous phosphatase with that caused by exogenously added, purified enzymes could potentially be misleading if dephosphorylation efficiency depended on association of both proteins and their relative positions within a regulatory complex. The approach used in this laboratory to establish that CFTR and a phosphatase are indeed associated, and identify the associated phosphatase using biochemical methods. Early speculation that the phosphatase might be physically associated with CFTR came from the striking deactivation of CFTR channels in excised patches. That possibility was eventually tested directly using co-immunoprecipitation and crosslinking approaches. Polyclonal antibodies were raised against four hydrophilic regions of PP2Cα, and the one with highest affinity against PP2Cα was purified and used for immunoprecipitations and immunocytochemistry studies of the PP2C preparations that have been tested including PP2Cα purified from turkey gizzard smooth muscle (from Dr. M. Pato, Univ. Saskatchewan, Canada), bacterially expressed human PP2Cα (from Dr. T.W. Cohen, Univ. Dundee, UK), α and β isoforms of mouse PP2C (from Dr. S. Tamura, Tohoku University, Sendai, Japan). When used for immunoblotting BHK and Calu-3 cells immunoprecipitated with the monoclonal anti-CFTR antibody M5A7, it recognizes a polypeptide of about 44 kD, consistent with known α and β isoforms of PP2C. PP1, PP2A and PP2B are not co-precipitated with CFTR under these conditions although they are readily detected in Western blots of cell lysates (Fig. 6).
AKAPs (A-kinase anchoring proteins), which localize CFTR (i.e., experiments. amino terminus of RII and disrupts its interaction with AKAPs (see ref. 104). The membrane-bound phosphatase is still referred to as "PP2C-like" because defined only by its functional and immunological properties. It may be a splice variant of the PP2Cα or β isoforms, a previously unidentified isozyme of PP2C, or perhaps a novel phosphatase that shares some characteristics with PP2C and happens to be recognized by the antibody. A proteomics approach based on co-purification of the phosphatase with CFTR without crosslinking mass spectrometry seems the most direct method for identification. 99 The main challenge has been the low expression of CFTR in mammalian cells and the low yield of phosphatase (< 0.2 moles PP2C / mole CFTR) in pulldowns.

The phosphatase may associate with CFTR directly like EBP_50,107,110 E3KARP,103 CAP70 111 as discussed above, or indirectly through an anchoring or scaffolding protein analogous to RACK1.105,106 Evidence that the association of PKA and CFTR has functional significance comes from the activation of CFTR channels in excised patches by cAMP-AMP alone, which indicates PKA holoenzyme is anchored near CFTR.104 PKCe also appears to be tethered near CFTR by the "regulator of C kinase" (RACK1).105 PP2C-like phosphatase probably does not associate with CFTR through one of the PDZ domain-containing proteins that have been found to interact with CFTR (i.e., EBP-50 107-110 E3KARP105 CAP70 107 or CAL112). Mutating the C-terminal "TRL" motif on CFTR to alanines, which disrupts PDZ domain binding, does not adversely affect the ability of CFTRHis10 to pull down phosphatase from BHK cell lysates.113 Once the physical basis of interactions between the phosphatase and CFTR is identified, it should be possible to introduce mutations into CFTR or the phosphatase that disrupt the interaction and reveal its physiological role. Establishing whether phosphatase effects are exerted directly rather than via other proteins in the regulatory complex may ultimately require reconstitution of the CFTR-phosphatase complex from purified components.

Is the Phosphatase Regulated?
Phosphatase activity could potentially be regulated through post-translational modifications of the phosphatase or through altered association with CFTR. This possibility remains speculative, however there are many precedents for regulation of serine/threonine phosphatases. The PP1 that dephosphorylates the cyclin-dependent kinase TPRK is itself inhibited by phosphorylation.114 PP2A is inhibited when phosphorylated on threonine and tyrosine residues,115 and is upregulated by methylation of its C-terminus.116 Moreover, methylation of PP2A is stimulated by cAMP, suggesting an interesting feedback loop between the phosphatase and PKA.117

PP2C is phosphorylated in an isoform-specific manner in mammalian cells and in yeast.119 PP2Cα becomes specifically phosphorylated on serines 375 and 377 when expressed heterologously in COS cells, sites that are phosphorylated by casein kinase II in vitro. Phosphorylation of PP2Cα is also enhanced two-fold by okadaic acid in vivo whereas the PP2B inhibitor cyclosporin has no effect, suggesting that PP2C is phosphorylated by casein kinase II.
Figure 6. Specific co-precipitation of a PP2C-like phosphatase with CFTR. BHK cells were lysed, immunoprecipitated, and resolved on 10% SDS-PAGE. Bands corresponding to all four protein phosphatase types were detected at these expected molecular masses when BHK crude cell lysates expressing wild-type CFTR (BHKwt) were immunoblotted using specific antibodies. None of the phosphatases were detectable when control cells lacking CFTR were precipitated using the anti-CFTR antibody M3A7. When cells expressing wild-type CFTR were immunoprecipitated with anti-CFTR antibody, PP2C was detected by immunoblotting but not the other phosphatases. (from ref. 97)

and dephosphorylated by PP1 and/or PP2A. The effect of such phosphorylation on the enzymatic activity of PP2C has not been studied in mammalian cells, however in yeast casein kinase II does regulate the PP2C orthologs Ptc2 and Ptc3 by phosphorylating serine residues in the conserved sequence (Ser-X-Ser-X-X-GluAsp) near their carboxyl termini.119 Phosphorylation inhibits Ptc2 activity by 25% and increases the phosphatase activity of Ptc3 by 55%. Preliminary experiments with pulled down CFTR phosphatase have not revealed any effect of casein kinase II pretreatment on dephosphorylation.

A novel regulatory mechanism involving fatty acids and Mg2+ was described for PP2Ca in bovine retina.120 A hallmark of PP2C is its requirement for relatively high divalent cation concentration, somewhat higher than the free concentration of Mg2+ typically available inside cells 0.7 – 0.9 mM.121 This Mg2+ dependence is consistent with the inhibition of CFTR rundown when free [Mg2+] is lowered from 2 mM to 0.5 mM.35 The metal dependence of retinal PP2C is shifted to lower Mg2+ concentrations by specific mono- and polysaturated fatty acids. Thus arachidonic acid (500 µM) causes a 10-fold stimulation of phosphatase activity when the Mg2+ concentration is 0.7 mM, and smaller stimulations are also observed for PP2Ca. Interestingly, arachidonic acid reduces CFTR currents when added to the cytoplasmic side of patches, and this inhibition is not voltage dependent or influenced by extracellular Cl- concentration suggesting it does not involve blockage of the pore.122 CFTR inhibition by fatty acids follows the sequence linoleic ≥ arachidonic ≥ oleic ≥ elaidic ≥ palmitic ≥ myristic, which is similar to the rank order of potency for inhibiting retinal PP2Ca. Studies of the effects of unsaturated fatty acids on CFTR dephosphorylation are in progress. Interestingly, cis-unsaturated fatty acids also inhibit PKA,123 hence they could downregulate CFTR channel activity through multiple mechanisms.

Future Prospects on Phosphatase Regulation of CFTR

Precise identification of the membrane-bound phosphatase and the cloning of its cDNA are major goals and will be essential for understanding the physiological regulation of CFTR channel activity. Two types of information are presently available that can be used as “handles” for such an undertaking. The first is functional (i.e., its Mg2+ dependence, pharmacology, etc), properties that have been deduced mainly from studies of CFTR rundown in excised patches, and have focused our attention on PP2C and its relatives in the PPM family. The second is the physical association of the phosphatase with CFTR, which has now been demonstrated by two methods and should facilitate purification and sequencing of the main protein regulating CFTR, although other phosphatases such as PP2A may play a role in some tissues. The low expression of CFTR will make the proteomic strategy challenging, however identifying the phosphatase and cloning its cDNA will be worth the effort. Detailed biochemical studies of CFTR phosphorylation/dephosphorylation will become possible with recombinant enzyme. The amino acid sequence of the phosphatase may also suggest sites of interaction with CFTR or targeting molecules, or consensus sites for post-translational modifications that regulate its phosphatase activity. The phosphatase has been proposed as a potential target for pharmacotherapies to treat cystic fibrosis121,124 and could be useful for treating those with CFTR mutations such as G551D that do not cause CFTR mislocalization, or as an adjunct to other therapies that only partially correct the chloride conductance defect. Conversely, activators of the phosphatase should inhibit CFTR-mediated chloride secretion in the gut and might find use in the treatment of secretory diarrhea, a major cause of infant mortality in the third world. Regardless, identifying and characterizing the phosphatase will break new ground and open many new avenues of research into the regulation of CFTR.

Acknowledgements

Phosphatase studies in this laboratory have been supported by the NH(NIDDK) and by the U.S. Cystic Fibrosis Foundation. T. Zhu and L.D. Howell are postdoctoral fellows of the Canadian Cystic Fibrosis Foundation. J.W. Hanrahan is a senior scientist of the Canadian Institutes of Health Research.

References

50

The Cystic Fibrosis Transmembrane Conductance Regulator


The Cystic Fibrosis Transmembrane Conductance Regulator

Chapter 3

Control of Membrane Transport by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)

Karl Kunzelmann

Abstract

In epithelial tissues of cystic fibrosis patients, the secretory CF transport is impaired, while the absorptive Na+ transport is enhanced. The disease causing cystic fibrosis transmembrane conductance regulator (CFTR) is a protein expressed primarily in luminal membranes of secretory and absorptive epithelial cells, along with other proteins in charge of epithelial transport. After initial characterization of CFTR as a cAMP and protein kinase A regulated Cl- channel, numerous studies reported influences of CFTR on other independent membrane transport proteins, such as epithelial Na+ channels, K+ and Cl- channels, as well as electroneutral transporters such as the Na+/H+ exchanger or the Cl/HCO₃⁻ antiporter. Currently best examined is the regulation of the epithelial Na⁺ channel ENaC by CFTR. The mechanisms for the inhibition of ENaC by CFTR are only slowly emerging. CFTR may control the membrane transport by other proteins not just by a single mechanism. CFTR’s first nucleotide binding domain plays a central role, the Cl- transport by CFTR affects other transport proteins, and the puzzle around the functional relationship of CFTR, ENaC and other transport proteins, has not yet been solved and the results may not even be the same in each cell type.

Introduction

The cystic fibrosis transmembrane conductance regulator (CFTR) plays a vital role for epithelial Cl- transport in both absorptive and secretory epithelial cells. CFTR is the only relevant luminal Cl- channel in the intestinal epithelium and probably also in sweat duct epithelial cells, and it is the important secretory channel in the airways. Mutations in the CFTR gene lead to a defect in CF secretion in these epithelial tissues. It has been proposed to be the cause for the clinical symptoms observed in cystic fibrosis. Mutations in the CFTR gene lead to a defect in CF secretion in these epithelial tissues. It has been proposed to be the cause for the clinical symptoms observed in cystic fibrosis. However, some of the transport defects observed in either in vivo measurements in cystic fibrosis patients, or in isolated tissues from CF patients or in transgenic mice, carrying CFTR mutations, could not easily be reconciled with the concept of a defective Cl- conductance as the only reason for the transport defects observed in CF.